OBJECTIVES: This paper aims to evaluate the anti-tumour properties of elatol, a compound (sesquiterpene) isolated from algae Laurencia microcladia. METHODS: In-vitro and in-vivo anti-tumour properties of elatol were investigated using: MTT assays to assess the cytotoxic effects; flow cytometry analysis to examine the cell cycle and apoptosis; Western blot analysis for determination of the expression of cell cycle and apoptosis proteins; and study of in-vivo tumour growth in mice (C57Bl6 mice bearing B16F10 cells). KEY FINDINGS: Elatol exhibited a cytotoxic effect, at least in part, by inducing cell cycle arrest in the G(1) and the sub-G(1) phases, leading cells to apoptosis. Western blot analysis demonstrated that elatol reduced the expression of cyclin-D1, cyclin-E, cyclin-dependent kinase (cdk)2 and cdk4. A decrease in bcl-xl and an increase in bak, caspase-9 and p53 expression was also observed. In the in-vivo experiment, treatment with elatol was able to reduce tumour growth in C57Bl6 mice. CONCLUSIONS: Elatol promotes a delay in the cell cycle, probably in the G(1)/S transition, activating the apoptotic process and this could be responsible, at least in part, for the in-vivo effects observed. Taken together, the in-vitro and in-vivo experiments suggested that elatol has anti-tumour properties. Further studies should be conducted to clarify the mechanism of action.
OBJECTIVES: This paper aims to evaluate the anti-tumour properties of elatol, a compound (sesquiterpene) isolated from algae Laurencia microcladia. METHODS: In-vitro and in-vivo anti-tumour properties of elatol were investigated using: MTT assays to assess the cytotoxic effects; flow cytometry analysis to examine the cell cycle and apoptosis; Western blot analysis for determination of the expression of cell cycle and apoptosis proteins; and study of in-vivo tumour growth in mice (C57Bl6 mice bearing B16F10 cells). KEY FINDINGS:Elatol exhibited a cytotoxic effect, at least in part, by inducing cell cycle arrest in the G(1) and the sub-G(1) phases, leading cells to apoptosis. Western blot analysis demonstrated that elatol reduced the expression of cyclin-D1, cyclin-E, cyclin-dependent kinase (cdk)2 and cdk4. A decrease in bcl-xl and an increase in bak, caspase-9 and p53 expression was also observed. In the in-vivo experiment, treatment with elatol was able to reduce tumour growth in C57Bl6 mice. CONCLUSIONS:Elatol promotes a delay in the cell cycle, probably in the G(1)/S transition, activating the apoptotic process and this could be responsible, at least in part, for the in-vivo effects observed. Taken together, the in-vitro and in-vivo experiments suggested that elatol has anti-tumour properties. Further studies should be conducted to clarify the mechanism of action.
Authors: Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss Journal: Med Res Rev Date: 2016-12-07 Impact factor: 12.944
Authors: Tara L Peters; Joseph Tillotson; Alison M Yeomans; Sarah Wilmore; Elizabeth Lemm; Carlos Jiménez-Romero; Luis A Amador; Lingxiao Li; Amit D Amin; Praechompoo Pongtornpipat; Christopher J Zerio; Andrew J Ambrose; Gillian Paine-Murrieta; Patricia Greninger; Francisco Vega; Cyril H Benes; Graham Packham; Abimael D Rodríguez; Eli Chapman; Jonathan H Schatz Journal: Clin Cancer Res Date: 2018-05-29 Impact factor: 12.531
Authors: Karen L Lang; Izabella T Silva; Lara A Zimmermann; Cíntia Lhullier; Maria V Mañalich Arana; Jorge A Palermo; Miriam Falkenberg; Cláudia M O Simões; Eloir P Schenkel; Fernando J Durán Journal: Mar Drugs Date: 2012-10-18 Impact factor: 6.085
Authors: Orlando Salvador-Neto; Simone Azevedo Gomes; Angélica Ribeiro Soares; Fernanda Lacerda da Silva Machado; Richard Ian Samuels; Rodrigo Nunes da Fonseca; Jackson Souza-Menezes; Jorge Luiz da Cunha Moraes; Eldo Campos; Flávia Borges Mury; José Roberto Silva Journal: Mar Drugs Date: 2016-01-25 Impact factor: 5.118